Immune-Monitoring Core Laboratory
The Immunomonitoring Core Laboratory (IMCL) is a state-of-the-art facility that monitors cell-mediated immune responses in clinical trials of new immune therapies and targeted drugs in cancer patients. Our dedicated staff offers expert advice to clinicians on the types of immune monitoring assays to choose for clinical trial monitoring and data interpretation. We are also engaged in developing new immune monitoring technology with industry and academic collaborators such as improved multi-parameter flow cytometry assays, tumor antigen epitope screening, and more sensitive non-radioactive CTL assays.
The IMCL also serves as a resource for MD Anderson, allowing investigators to use dedicated equipment not usually available in individual labs, such as ELISPOT readers and multiplex cytokine measurement instruments (e.g., Luminex and MSD platforms). We also participate in national consortiums with other immune monitoring labs across the U.S. such as the CVC to standardize and validate immune assays and set rigorous quality control standards.
The IMCL is full member of MD Anderson’s CCSG core lab program. It is located at the South Campus Research Building I (SCR1) in the Center for Cancer Immunology Research (CCIR).